Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study.

ABSTRACT:

Background

Malaria, caused by Plasmodium falciparum and Plasmodium vivax, is commonly reported in Ethiopia. The World Health Organization (WHO) recommends treating P. vivax malaria with a schizonticidal drug and a 14-day course of primaquine (0.25-0.5 mg/kg body weight daily) to prevent relapses. In 2018, Ethiopia adopted a policy of primaquine radical cure (0.25 mg/kg for 14 days), with close monitoring for adverse events, but without prior glucose-6-phosphate dehydrogenase (G6PD) testing. This study aimed to assess the safety of this policy by monitoring the risk of haemolysis and other adverse events following the administration of primaquine.

Methods

A prospective observational study was conducted from May 2019 to June 30, 2021, enrolling patients with P. vivax and mixed

SUBMITTER: Shifraw T 

PROVIDER: S-EPMC12797556 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature